U.S. FDA panel votes against Spectrum's lung cancer drug


Bywire - Claim your free account nowBywire - Claim your free account now

- Advisers to the U.S Food and Drug Administration on Thursday voted against recommending Spectrum Pharmaceuticals' experimental drug to treat patients with a form of non-small cell lung cancer.

(Reporting by Khushi Mandowara and Mrinalika Roy; Editing by Shailesh Kuber)

Bywire will email you from time to time with news digests, stories & opportunities to get involved. Privacy

Bywire - Claim your free account nowBywire - Claim your free account now